Latest Transformation News

Black Dragon Gold has applied for its Salave Gold Project to be designated a Strategic Investment Project under new regional legislation in Asturias, aiming to fast-track development and boost local economic benefits.

Riversgold Ltd reveals a highly promising 12-kilometre gold corridor at its Tambourah project in Pilbara, with rock-chip samples grading up to 101 g/t Au. Exploration plans are underway to refine drill targets as conditions improve.

Ansell Limited has delivered a robust first half for FY25, reporting a near 30% increase in revenue and a remarkable 183.5% jump in net profit, driven by strong segment growth and strategic acquisition integration.

Opyl Limited has entered a strategic partnership with Avion, integrating its AI-powered TrialKey platform to enhance clinical trial design and execution across the APAC region.

Sigma Healthcare has raised its FY25 normalised EBIT guidance to $64-$70 million, driven by robust operational performance and the successful rollout of a key supply contract with Chemist Warehouse.

Pact Group Holdings has responded to an ASX price query, confirming no undisclosed material information and previewing a modest earnings uplift for the half-year ending December 2024.

PARKD has inked a pivotal five-year exclusive licensing agreement with Fielders, a BlueScope Steel division, to commercialise its innovative MDSB® and MDSS® products in Australia and explore international expansion.

AdAlta Limited is accelerating its 'East to West' cellular immunotherapy strategy, aiming to bridge Asian innovation with Western clinical development and manufacturing to target solid cancers. The company plans to secure three assets by the end of 2025 and initiate clinical trials, positioning itself as a leader in this emerging market.

Nick Scali Limited reported a stronger-than-expected half-year profit, driven by solid ANZ performance, while its UK operations continue to face restructuring challenges amid store refurbishments.

News Corporation reported a robust half-year performance with revenues up 4% to $4.33 billion and net income soaring 80% to $334 million, while advancing its strategic pivot through the planned sale of Foxtel.

Neuren Pharmaceuticals has secured a pivotal FDA Type C Meeting to discuss primary efficacy endpoints for its Phase 3 trial of NNZ-2591 targeting Phelan-McDermid syndrome, advancing its rare disease drug development.

WT Financial Group has reported a robust half-year performance for H1 FY2025, with revenue up 33.5% and underlying net profit before tax rising 35.8%, underscoring its strong position in Australia's wealth management sector.